Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancer with a 5-year survival rate below 10%. Two of the major contributors to this dismal prognosis are late-stage diagnosis and limited treatment options. Common symptoms of PDA ...
In 2019, Pancreatic Cancer (PC) is the 3rd leading cause of cancer-related deaths in the USA with 94% dying within 5 years of diagnosis. 90% of PC is Pancreatic Ductal Adenocarcinoma (PDA), of which >80% overexpress a hypo-glycosylated form the me...
Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer-related deaths in the US, and breast cancer (BC) contributes to ~40,000 deaths annually. The development of novel therapeutic agents for improving patient outcome is of para...
MUC1 is a heavily glycosylated transmembrane glycoprotein which is overexpressed and aberrantly glycosylated in most human carcinomas. MUC1 contains a large tandem repeat, a short transmembrane, and a small cytoplasmic tail. Both tandem repeat and...
MUC1 is a heavily glycosylated transmembrane glycoprotein which is overexpressed and aberrantly glycosylated in most human carcinomas. MUC1 contains a large tandem repeat, a short transmembrane, and a small cytoplasmic tail. Both tandem repeat and...
Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer-related deaths in the US. An understanding of the molecular pathogenesis of PDA is of utmost importance to be able to improve the current or design new targeted therapies fo...
Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer-related deaths in the US. An understanding of the molecular pathogenesis of PDA is of utmost importance to be able to improve the current or design new targeted therapies fo...
